Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Vevo Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Vevo Therapeutics

Vevo Therapeutics

Seed

San Francisco-based Vevo Therapeutics uses AI and in vivo platforms for innovative biotech solutions.

HQ
San Francisco, CA, US
Founded
2022
Overview
Compare
Fundraising
Employees
Website

Vevo Therapeutics, founded in San Francisco, California, is a biotechnology startup dedicated to discovering better treatments for a broader range of patients. The company leverages its Mosaic in vivo drug discovery platform and advanced AI algorithms to scale in vivo experiments, aiming to revolutionize the drug discovery process. Vevo Therapeutics focuses on integrating in vivo data with AI to identify superior drug targets and develop more effective treatments, addressing the limitations of traditional test tube-based drug discovery methods.

Notable figures affiliated with Vevo Therapeutics include a team of experts in biotechnology and artificial intelligence, though specific names are not provided. The company has attracted significant attention from investors interested in cutting-edge biotech solutions. Key achievements include the successful development and implementation of their scalable in vivo experiment platform, which has the potential to transform the landscape of drug discovery. Vevo Therapeutics' innovative approach is poised to make a substantial impact on the biotech industry by improving the efficacy and reach of new treatments.

Vevo Therapeutics - Quick Facts

When was Vevo Therapeutics founded?

Vevo Therapeutics was founded in 2022.

Where is Vevo Therapeutics' headquarters located?

Vevo Therapeutics' headquarters is located in San Francisco, CA, US.

When was Vevo Therapeutics' last funding round?

Vevo Therapeutics' most recent funding round was for $12M (USD) in December 2022.

How much has Vevo Therapeutics raised to-date?

As of Dec 8, 2022, Vevo Therapeutics has raised a total of $12M (USD).

How many employees does Vevo Therapeutics have?

Vevo Therapeutics has 19 employees as of Feb 4, 2024.

Vevo Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • AI Operations
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software